Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2

Abstract

Bilateral vestibular schwannomas are the hallmark of neurofibromatosis type 2 (NF2), and these tumors impair hearing and frequently lead to deafness. Neurosurgical intervention, the only established treatment, often damages the vestibular nerve. We report 2 cases in which treatment with bevacizumab (for 3 months in one case and 6 months in the other) induced regression of progressive vestibular schwannomas by more than 40% and substantially improved hearing in the patient treated for 6 months. Bevacizumab therapy may thus provide an effective treatment for progressive vestibular schwannomas in patients with NF2.

Bibliografische Daten

OriginalspracheEnglisch
ISSN1522-8517
DOIs
StatusVeröffentlicht - 01.01.2010
PubMed 20150363